TruScreen Group (ASX:TRU) has opted to launch a five-year cervical cancer screening run in Vietnam’s Ho Chi Minh City.
Alongside Ho Chi Minh City Public Health Association (PHA) and a third-party player, Gorton Health Services (GHS), a three-way MOU has underpinned the program, which is set to commence in Q1 next year.
Some 260,000 women are envisioned as participating in the trial, set to run up into the late 2020s.
“TruScreen was selected by [HPA] for its unique real time, non-invasive, objective cervical cancer screening technology, requiring no pathology infrastructure, that suits the screening program,” the company wrote on Monday.
Truscreen is a device where a one-use probe that touches the cervix is attached to a handheld device wherein – perhaps unsurprising for 2024 – the company asserts its AI tech can detect cancer at superior rates to other technologies.
On its website, the company insinuates the device is best placed for usage in less-developed countries (“emerging markets”) or communities where access to first-rate healthcare is likely unavailable.
“We are increasingly recognised by key government agencies of the ability for TruScreen to be rolled out quickly and economically in large population-based screening programs,” TruScreen CEO Marty Dillon said.
“The signing of this MOU further reinforces our TruScreen non- invasive and real time screening as a technology particularly suited for use in low-and- middle income countries.”
TRU last traded at 1.9cps.
Join the discussion: See what HotCopper users are saying about TruScreen and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
